Other languages Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Market Closed - Nasdaq Other stock markets 02:00:00 21/05/2024 am IST			5-day change	1st Jan Change
0.6199 ^USD	+1.62%		-8.18%	+82.22%

09/05	Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04	Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	16/04
Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients	10/04
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program	05/03
Sector Update: Health Care Stocks Gain Late Afternoon	23/02
Sector Update: Health Care	23/02
Monopar Therapeutics Shares Rise on 'Promising' Preclinical Cancer Treatment Trial Results	23/02
Top Midday Gainers	23/02
Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers	22/02
Sector Update: Health Care Stocks Softer Tuesday Afternoon	21/02
Monopar Therapeutics Gets Clearance to Start Phase 1 Trial in Advanced Cancers in Australia	20/02
Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers	20/02
Monopar Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Investors Await Fed Decision as US Futures Move Lower in Wednesday's Premarket Activity	01/11
Top Premarket Gainers	01/11
Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society Annual Meeting	01/11
Monopar Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
Monopar Therapeutics Reports Positive Clinical Data From Camsirubicin Therapy Trial	08/23/08
Monopar Therapeutics Inc. Provides Update on Camsirubicin Clinical Trial	08/23/08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Other languages

Filters